US SEC Trading Suspension Halt Orders — October 26, 2026

NYSE delisting of common shares under a Plan of Sale and Liquidation; OTC trading may begin but is not assured, and the board retains power to terminate the plan, making the outcome path-dependent

Nasdaq granted 180 extra days (to April 19, 2027) to regain $1.00 minimum bid compliance, so the listing is not at immediate risk but the stock has traded below $1 since the April 23, 2026 notice

NYSE immediately suspending trading in EVEXW public warrants (exercise price $11.50) for abnormally low selling price, signalling the warrants are deeply out of the money while common stock (EVEX) continues trading

Common stock EVEX is unaffected by the warrant suspension and continues on the NYSE, so the action is isolated to the derivative instrument rather than the equity

Sale of 19 multifamily assets to an affiliate of Cortland Partners, LLC is part of the wind-down, which may crystallize asset value for distributions, though no per-share amounts were disclosed

Common shares are being removed from the NYSE, reducing liquidity and index eligibility; OTC trading is not guaranteed

Filing flags possible legal proceedings tied to the sale of 19 multifamily assets to a Cortland Partners affiliate, creating litigation overhang during liquidation

Filing carries risk disclosure around REIT tax status during dissolution and transfer to a Liquidating Trust

Company has been below the $1.00 Nasdaq minimum bid since at least April 2026 and there is no assurance it will regain compliance by April 19, 2027

NYSE is commencing proceedings to delist EVEXW due to abnormally low selling price, and the warrants will cease trading once the SEC application completes

Suspension signals the market price of the associated instrument is well below its $11.50 exercise price; continued common-stock listing remains subject to other NYSE standards

Liquidating trust structure could return residual asset value to holders once assets and liabilities are transferred, though amounts were not disclosed in the filing

If OTC trading begins as anticipated, holders retain a secondary market for shares during the wind-down period

180-day extension gives management time to execute a reverse split or price recovery; a successful bid-price recovery would remove a major listing overhang

Warrant suspension does not affect EVEX common equity, so investors can express a view on the common without warrant-specific dilution or exercise mechanics

Two of three filings (Zeo on Nasdaq, Eve on NYSE) involve price-based listing deficiencies, indicating exchange enforcement of minimum price standards is active in the period

Elme's voluntary dissolution and asset sale to an affiliate reflects a broader pattern of REITs liquidating portfolios and returning capital via liquidating trusts

The Eve action targets warrants rather than common stock, showing exchanges will delist out-of-the-money derivative securities while leaving the underlying equity listed

Monitor NYSE delisting effective date, OTC quotation start, and Liquidating Trust formation; filing date October 23, 2026 press release

Watch for any board action to terminate the Plan of Sale and Liquidation, which would reverse the delisting path

Track closing bid price versus $1.00 and any reverse-split proposal ahead of the April 19, 2027 deadline

Monitor SEC filing acceptance and final delisting date for public warrants following the October 21, 2026 NYSE notice

Watch EVEX for any further NYSE continued-listing notices given the warrant action

Track any litigation related to the 19-asset Cortland Partners sale that could affect distributable proceeds